9d agoSeeking AlphaNEUTRAL 50M&A
Personalis, Inc. (PSNL) M&A Call Transcript
Personalis, Inc. (PSNL) M&A Call July 20, 2026 9:00 AM EDTCompany ParticipantsElizabeth Krutoholow - Vice President of Investor Relations &...
Archived explainer. For the current picture see today's PSNL page.
Why Is PERSONALIS INC (PSNL) Stock Moving Today?
By the Top Tier Newswire AI Desk · July 21, 2026 at 5:08 AM ET · reviewed against 20 wire stories
PERSONALIS INC (PSNL) is drawing unusual attention today. Our newswire has captured 20 stories on PSNL across 13 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Why PSNL stock is moving today
Personalis Inc. (PSNL) shares are moving sharply lower today, down approximately 10% as of the latest data. The stock is reacting to a definitive merger agreement announced by Tempus AI, Inc. to acquire Personalis in an all-stock deal valued at $1.5 billion. The deal is expected to strengthen Tempus AI’s precision oncology business but has triggered immediate market skepticism, with both PSNL and TEM shares falling.
What Happened
On July 20, 2026, Tempus AI, Inc. announced a definitive merger agreement to acquire Personalis. The deal is intended to enhance Tempus AI’s position in minimal residual disease (MRD) testing and expand its biopharma data capabilities. The merger was detailed in a published slide deck and discussed in an M&A call with investors. However, the market has responded negatively, with Tempus AI shares falling about 8% and Personalis shares declining in tandem.
Analysts have offered mixed reactions. Needham cut Personalis’ stock rating, while Morgan Stanley expressed cautious optimism about the strategic value of the acquisition. Retail traders on social media platforms are also discussing the deal, with some calling the price per share of $16.25 a potential floor for the stock.
What The Data Shows
Personalis has a market cap of $1.6 billion and is currently unprofitable, with a trailing twelve-month (TTM) earnings per share (EPS) of -1.02 and revenue declining by 24.7% TTM. The stock has traded between $3.84 and $16.39 over the past 52 weeks. Recent insider activity has also been bearish, with eight insider sales totaling $7.1 million in the last 90 days, the most recent on July 15. The stock is also trading with a beta of 2.24, indicating high volatility relative to the broader market.
What To Watch
Personalis is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any changes in the stock rating from key firms like Needham and BTIG. Additionally, the market’s reaction to the merger’s integration progress and long-term strategic value will be crucial to the stock’s performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
PSNL by the numbers
Coverage: 20 stories / 13 sourcesAI sentiment: 56/100 (mixed)Mkt cap: $1.6B52w: $3.84 to $16.39
The headlines behind the move
9d agoSeeking AlphaNEUTRAL 50M&A
Personalis, Inc. (PSNL) Tempus AI, Inc. - M&A Call - Slideshow
2026-07-20. The following slide deck was published by Personalis, Inc.
9d agoTipRanksBULLISH 63M&A
Tempus AI Announces Merger Agreement to Acquire Personalis
Tempus AI, Inc. Class A ( ($TEM) ) just unveiled an announcement. On July 20, 2026, Tempus AI, Inc. signed a definitive merger agreement to acquire genomics company...
9d agoTipRanksBEARISH 42M&A
Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a “Market Misread”
Tempus AI ($TEM) stock fell about 8% on Monday after the health technology company said it will acquire biotechnology company Personalis ($PSNL) in an all-stock dea...
9d agoStocktwits NewsBULLISH 56M&A
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal
The brokerage said the acquisition strengthens Tempus AI’s precision oncology business, though near-term financials are less compelling.
9d agoInvesting.com Analyst RatingsBEARISH 32Analyst
Needham cuts Personalis stock rating on Tempus AI acquisition
Needham cuts Personalis stock rating on Tempus AI acquisition
9d agoYahoo FinanceBULLISH 63M&A
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou
9d agoInvestors.comBEARISH 34M&A
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on PSNL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier PSNL move explainers: 2026-07-21 · 2026-07-20